Focus:
Central Nervous System
-
15 January 2020 whitepapers
Case Study: Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City that specialises in discovering, developing and delivering innovative medicines for patients with serious diseases.
-
20 December 2019 News
Janssen’s esketamine nasal spray approved in the EU
The European Commission (EC) has approved Johnson & Johnson subsidiary Janssen’s Spravato (esketamine) nasal spray for treatment-resistant major depressive disorder.
-
9 December 2019 Research Reports
Huge unmet needs in glioblastoma multiforme market drives the future, says GlobalData
Glioblastoma multiforme (GBM), also known as Grade IV astrocytoma, is the most aggressive form of brain cancer and has one of the highest unmet needs in the oncology market. The...
-
29 November 2019 News
Neuraxpharm expands Southern Europe operations with Portugal unit
European speciality pharmaceutical company Neuraxpharm Group has announced the launch of Neuraxpharm Portugal as part of an expansion of its operations in Southern Europe.
-
28 November 2019 Research Reports
Biomarkers will play a key role in shaping the global CNS drug market, although cost remains a limiting factor, says GlobalData
A biomarker acts as an internal ‘fingerprint’, indicating the presence of biological conditions, pathogens, and processes. These small molecules have been long used in clinical research, and provide a unique...
-
19 November 2019 News
Alkermes to acquire Rodin Therapeutics in $950m deal
Irish biopharmaceutical company Alkermes has agreed to buy US-based neuroscience-focused firm Rodin Therapeutics under a deal worth up to $950m.
-
18 November 2019 News
Jazz Pharma’s sleepiness drug solriamfetol gets CHMP recommendation
Jazz Pharmaceuticals has secured a positive opinion from a European Medicines Agency (EMA) panel for solriamfetol to improve wakefulness and decrease excessive daytime sleepiness (EDS) in adults with narcolepsy or...
-
15 November 2019 News
Sarepta and StrideBio sign gene therapy development deal
Sarepta Therapeutics has partnered with StrideBio for the development of in-vivo adeno-associated viral (AAV) based therapies for up to eight targets of the central nervous system (CNS) and neuromuscular conditions.
-
13 November 2019 News
US researchers launch neurohub for brain disease therapies
US researchers have launched a research network, Weill Neurohub, to develop treatments for brain and nervous system diseases and disorders.
-
4 November 2019 News
Alzheimer’s drug Oligomannate gets conditional approval in China
Chinese pharmaceutical firm Shanghai Green Valley Pharmaceuticals has secured conditional approval from the country’s regulatory agency for Oligomannate (GV-971) to improve cognitive function in mild to moderate Alzheimer's disease patients.